mofezolac and rivaroxaban

mofezolac has been researched along with rivaroxaban in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boccarelli, A; Cabral, LM; de Pádula, M; Di Mauro, GD; Ferorelli, S; Fortuna, CG; Iaselli, M; Miciaccia, M; Pati, ML; Perrone, MG; Rodrigues Pereira da Silva, LC; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vacca, A; Vitale, P	1

Other Studies

1 other study(ies) available for mofezolac and rivaroxaban

Article	Year
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. European journal of medicinal chemistry, 2019, Feb-15, Volume: 164 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship	2019

Article

Year

Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.

European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship

2019